NASDAQ$ATRC
Atricure Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported a 17.9% year-over-year increase in worldwide revenue, driven by strong adoption trends and new product launches.
AtriCure reported strong third-quarter results, with worldwide revenue increasing by 17.9% year-over-year to $115.9 million. The company experienced growth across key product lines and geographies, driven by the adoption of its products and the launch of new products. AtriCure also generated positive cash flow and improved profitability.
- Worldwide revenue increased by 17.9% year-over-year to $115.9 million.
- U.S. revenue increased by 16.8% year-over-year to $95.5 million.
- International revenue increased by 23.3% year-over-year to $20.5 million.
- Generated positive cash flow of $16.3 million in the third quarter.
Headline financials
Revenue & EPS history
Atricure · Revenue · Quarterly
$116M
Revenue by segment
Atricure · $93.5M total across 8 segments · Q1 2023
- Appendage Management (U.S.)$32.3M—34.6%
- Open Ablation (U.S.)$25.1M—26.9%
- Pain Management (U.S.)$11.1M—11.8%
- Minimally Invasive Ablation (U.S.)$9.64M—10.3%
- Open Ablation (International)$7.29M—7.8%
- Appendage Management (International)$5.92M—6.3%
- Minimally Invasive Ablation (International)$1.87M—2.0%
- Pain Management (International)$228K—0.2%
Forward guidance
AtriCure expects full year 2024 revenue of approximately $459 million to $462 million, reflecting growth of approximately 15% to 16%. Management continues to expect full year 2024 Adjusted EBITDA of approximately $26 million to $29 million. Full year 2024 adjusted loss per share is expected to be in the range of $0.74 to $0.80.
Tailwinds
- Revenue growth of approximately 15% to 16% is expected for full year 2024.
- Adjusted EBITDA is expected to increase by 34% to 49% over full year 2023.
- Continued improvement in profitability.
- Ongoing adoption trends throughout the business.
- Expansion of access to innovative solutions for patients and providers worldwide.
Headwinds
- Full year 2024 adjusted loss per share is expected to be in the range of $0.74 to $0.80.
- Normal seasonality of procedures in summer months.
- Less favorable geographic and product mix impacted gross margin.
- Uncertainties related to future events could affect actual results.
- Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP financial measures.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+0.7%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.3%
Avg return
30 days after
48%
31 / 64 earnings
Positive
+21.1%
Q3 2024
Best reaction
-13.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.0% | -10.5% | -7.9% | |
| Q4 2025 | -2.3% | -3.6% | -11.5% | |
| Q3 2025 | -3.7% | -7.6% | +1.9% | |
| Q1 2025 | -13.7% | -16.1% | -0.2% | |
| Q4 2024 | -6.5% | -9.8% | -21.4% | |
| Q3 2024 | +21.1% | +16.6% | +25.8% | |
| Q2 2024 | -1.8% | +0.4% | +17.6% | |
| Q1 2024 | -7.9% | -8.4% | -6.6% | |
| Q4 2023 | +0.6% | +1.4% | -1.2% | |
| Q3 2023 | +5.6% | +9.3% | +5.6% | |
| Q2 2023 | +8.2% | +3.8% | -14.6% | |
| Q1 2023 | +7.1% | +7.1% | +1.5% | |
| Q4 2022 | +5.3% | -1.3% | -5.9% | |
| Q3 2022 | -4.2% | -5.9% | +9.1% | |
| Q2 2022 | +1.1% | +4.3% | -11.9% | |
| Q1 2022 | -2.6% | -17.8% | -21.4% | |
| Q4 2021 | +5.8% | -3.8% | +2.2% | |
| Q3 2021 | +10.0% | +9.2% | -16.0% | |
| Q2 2021 | -2.5% | -5.4% | -8.6% | |
| Q1 2021 | +5.8% | +16.8% | +11.5% | |
| Q4 2020 | -4.3% | +0.1% | -4.3% | |
| Q3 2020 | +0.2% | +6.8% | +25.8% | |
| Q2 2020 | -7.2% | -10.7% | -8.8% | |
| Q1 2020 | +10.0% | +4.7% | +22.0% | |
| Q4 2019 | -3.8% | -10.1% | -37.9% | |
| Q3 2019 | -2.8% | +4.4% | +8.7% | |
| Q2 2019 | +1.3% | -0.3% | -13.9% | |
| Q1 2019 | +4.8% | +7.4% | +5.5% | |
| Q4 2018 | -5.6% | -8.4% | -17.8% | |
| Q3 2018 | -1.4% | +0.7% | +5.3% | |
| Q2 2018 | +11.2% | +7.2% | +20.6% | |
| Q1 2018 | +9.5% | +7.8% | +18.2% | |
| Q4 2017 | +5.5% | +1.9% | +11.2% | |
| Q3 2017 | -8.7% | -12.3% | -13.6% | |
| Q2 2017 | +3.0% | -0.4% | -7.8% | |
| Q1 2017 | +9.4% | +5.5% | +2.0% | |
| Q4 2016 | +4.9% | -5.5% | +1.1% | |
| Q3 2016 | +7.3% | +9.0% | +17.5% | |
| Q2 2016 | -10.7% | -4.2% | +4.8% | |
| Q1 2016 | -10.4% | — | — | |
| Q4 2015 | -5.5% | — | — | |
| Q3 2015 | -0.7% | — | — | |
| Q2 2015 | +14.5% | — | — | |
| Q1 2015 | +7.6% | — | — | |
| Q4 2014 | -4.4% | — | — | |
| Q3 2014 | +2.8% | — | — | |
| Q2 2014 | -4.4% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q4 2013 | -0.9% | — | — | |
| Q3 2013 | +1.1% | — | — | |
| Q2 2013 | +0.9% | — | — | |
| Q1 2013 | +9.1% | — | — | |
| Q4 2012 | +5.6% | — | — | |
| Q3 2012 | +20.3% | — | — | |
| Q2 2012 | -6.7% | — | — | |
| Q1 2012 | -5.1% | — | — | |
| Q4 2011 | -4.7% | — | — | |
| Q3 2011 | -5.0% | — | — | |
| Q2 2011 | -13.2% | — | — | |
| Q1 2011 | +2.6% | — | — | |
| Q4 2010 | +2.6% | — | — | |
| Q3 2010 | -0.6% | — | — | |
| Q2 2010 | -0.4% | — | — | |
| Q1 2010 | -1.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro